Search | Clinical Trials Finder

ClinicalTrials.gov public records Last synced Sep 29, 2026, 7:31 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–14 of 14 matching trials from the live ClinicalTrials.gov search.

Local D1 index available.

Filters: Sponsor: Anderson Clinical Research Clear all

Conditions: Prostate Cancer
Interventions: Cabozantinib, Androgen Ablation Therapy; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: Male only
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2021
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Colorectal Cancer
Interventions: Interviews - Colorectal Cancer Participants, Questionnaire, Focus Groups, Interviews - Caregivers of Colorectal Cancer Participants; Behavioral
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 21 Years and older
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2022
U.S. locations: 3
States / cities: San Francisco, California • Houston, Texas

Conditions: Prostate Cancer
Interventions: Ipilimumab; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Pleuropulmonary Blastoma, Sertoli-Leydig Cell Tumor, DICER1 Syndrome, Cystic Nephroma, Wilms Tumor, Pineoblastoma, Renal Sarcoma, Nodular Hyperplasia of Thyroid, Nasal Chondromesenchymal Hamartoma, Ciliary Body Medulloepithelioma, Neuroblastoma, Pituitary Cancer, Embryonal Rhabdomyosarcoma, Ovarian Sarcoma, Gynandroblastoma, Thyroid Carcinoma, Embryonal Rhabdomyosarcoma of Vagina (Diagnosis), Embryonal Rhabdomyosarcoma of Uterus (Diagnosis), Embryonal Rhabdomyosarcoma of Cervix
Interventions: Not listed
Lead sponsor: Children's Hospitals and Clinics of Minnesota; Other
Eligibility: 0 Minutes to 100 Years
Enrollment: 3,400 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2035
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Chronic Phase Chronic Myeloid Leukemia
Interventions: Imatinib, Dasatinib; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 262 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2022
U.S. locations: 21
States / cities: Anaheim, California • Fontana, California • Los Angeles, California + 18 more

Conditions: Leukemia
Interventions: QUALMS-1 Questionnaire, FACT-An Questionnaire; Behavioral
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2022
U.S. locations: 6
States / cities: Tampa, Florida • Baltimore, Maryland • Boston, Massachusetts + 3 more

Conditions: CIN 2/3, HPV Infection, Pre-Cancerous Dysplasia, Cervical Dysplasia, HPV Related Disease
Interventions: Artesunate vaginal insert, Placebo vaginal insert; Drug
Lead sponsor: Frantz Viral Therapeutics, LLC; Industry
Eligibility: 25 Years to 100 Years · Female only
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 7
States / cities: Fort Myers, Florida • Ann Arbor, Michigan • Cleveland, Ohio + 2 more

Conditions: Breast Neoplasms
Interventions: Not listed
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: Female only
Enrollment: 34,359 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Melanoma
Interventions: Questionnaire; Behavioral
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2016
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Mycobacterium Avium-Intracellulare Infection, HIV Infections
Interventions: Rifapentine, Ethambutol hydrochloride, Clarithromycin, Azithromycin; Drug
Lead sponsor: Anderson Clinical Research; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Hampton, Virginia

Conditions: Smoking Cessation
Interventions: Bupropion SR, Placebo; Drug · Other
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years and older · Female only
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Houston, Texas

Conditions: COVID-19, Lymphocytopenia
Interventions: CYT107, Placebo; Drug
Lead sponsor: Revimmune; Industry
Eligibility: 25 Years to 80 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 2
States / cities: New York, New York • Houston, Texas

Conditions: Advanced Malignant Solid Neoplasm
Interventions: EphA2-targeting DOPC-encapsulated siRNA, Laboratory Biomarker Analysis, Pharmacological Study; Drug · Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Leukemia
Interventions: LY2510924, Idarubicin, Cytarabine; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years to 70 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Houston, Texas

Search by objective public record fields.

Cabozantinib and Androgen Ablation in Patients With Androgen-Dependent Metastatic Prostate Cancer

Patient-Centered Risk Adjusted Surveillance After Curative Resection of Colorectal Cancer

T-Cell Responses to Neoantigens Post Treatment With Ipilimumab in Men With Metastatic Castration-Resistant Prostate Cancer

International PPB/DICER1 Registry

Study of Dasatinib vs Imatinib in Patients With Chronic Myeloid Leukemia (CML) Who Did Not Have Favorable Response to Imatinib

Interventional Validation of an MDS-Specific Measure of Quality of Life: Assessing the Responsiveness of the Quality of Life in Myelodysplasia Scale (QUALMS-1) to Different Hypomethylating Agent Regimens for Low and Intermediate Risk Disease

Artesunate Vaginal Inserts for the Treatment of Cervical Intraepithelial Neoplasia (CIN2/3)

Post-Treatment Surveillance in Breast Cancer: Bringing CER to the Alliance

Prospective Measurement of Post-Treatment Lymphedema

Tolerance, Safety, and Activity of Rifapentine Alone and in Combination Therapy in AIDS Patients With Mycobacterium Avium Complex Bacteremia.

Double-blind, Placebo-Controlled Pilot Study of Bupropion to Promote Smoking Cessation During Pregnancy

InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic Patients With COVID-19 Infection ( ILIAD-7-US-O )

EphA2 siRNA in Treating Patients With Advanced or Recurrent Solid Tumors

LY2510924, Idarubicin and Cytarabine in Patients With Relapsed or Refractory Acute Myeloid Leukemia